Back to Top
Immune Checkpoint Articles
-
-
September 01, 2023
Introduction ...
-
September 05, 2022
Introduction
Programmed...
-
September 01, 2022
Researchers from the Dana-Farber Cancer Institute and Harvard Medical School have conducted a comprehensive comparison of commonly used monoclonal antibodies (mAbs) targeting the PD-1/PD-L1 pathway in mice. Their findings, recently published in the journal Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, provide valuable insights for modeling cancer immunotherapy in preclinical studies.
The PD-1/PD-L1 pathway is a critical immune... -
April 22, 2022
Introduction
In advancing cancer immunotherapy, antibodies against PD-1 have become a breakthrough and opened a new door for severely affected cancer patients. Nevertheless, the results of preclinical studies have faced various obstacles in transforming into successful clinical...
-
April 01, 2022
Introduction
As...
-
November 10, 2020
Introduction
The...
